A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction With High Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma.

Trial Profile

A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction With High Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Bortezomib (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms Mel-Vel
  • Most Recent Events

    • 07 Jun 2016 Results of an updated analysis of 2 studies (NCT00784823; n=29 and NCT01242267; n=32) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 17 Jul 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Jul 2013 Planned end date changed from 1 Dec 2009 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top